San Francisco, CA, July 29, 2022 – FlemingMartin is pleased to announce that Nurix Therapeutics (NASDAQ: NRIX), a biotechnology company focused on discovering and developing drugs to treat cancer (including novel, small molecule immuno-oncology agents), has hired Eric Schlezinger as Chief People Officer. In advancing and leading a best-in-class HR function, Eric will help maximize business results via deftly leveraging Nurix’s human capital.
Eric brings over 25 years of both human resources and legal expertise to Nurix, as his career has spanned multiple industries and functions. Most recently, Eric skillfully led the People departments for Pendulum Therapeutics, VIR Biotechnology (NASDAQ: VIR), and Adamas Pharmaceuticals (formerly, NASDAQ: ADMS, then acquired by Supernus Pharmaceuticals for $400 Million in 2021). Earlier in his career, Eric held the positions of SVP of Global Business Strategy and HR at Xperi Holding Corp. (NASDAQ: XPER), as well as EVP, General Counsel and Secretary at Dialogic Inc. (NASDAQ: DLGC). Eric earned his JD from Washington University in St. Louis and he received his bachelor’s degree from Dartmouth College. To learn more, please read Nurix Therapeutics’ Chief People Officer Announcement.
Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Their small molecule drugs are designed to modulate protein levels in cells as a new therapeutic approach for a broad range of diseases, including immune-oncology and autoimmune disease. To learn more, visit www.nurixtx.com.
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs of companies to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. www.flemingmartin.com